Guido Koopmans PhD

Dr. Guido Koopmans is a neuroscientist and Co-founder of Algiax Pharmaceuticals with over 15 years of experience in pain research and clinical development. As Chief Scientific Officer at Algiax Pharmaceuticals, he’s led the development of AP-325, a novel dual-target pain therapeutic now in Phase II trials. He’s passionate about translating neuroscience into real-world therapies and thrives at the intersection of science, strategy, and innovation.